Cefotaxime, vial 1g + solvent ampoule 5ml – Biochemist

Composition

Powder – 1 fl. :

cefotaxime (in the form of sodium salt) 1 g

Pharmacological action

Cephalosporin antibiotic of the third generation of a broad spectrum of action. It has a bactericidal effect by inhibiting the synthesis of the bacterial cell wall. The mechanism of action is caused by acetylation of membrane-bound transpeptidases and disruption of cross-linking of peptidoglycans, which is necessary to ensure the strength and rigidity of the cell wall.

Highly active against gram-negative bacteria (resistant to other antibiotics): Escherichia coli, Citrobacter spp., Proteus mirabilis, Providencia spp., Klebsiella spp., Serratia spp., some strains of Pseudomonas spp., Haemophilus influenzae.

It is less active against Streptococcus spp. (including Streptococcus pneumoniae), Staphylococcus spp., Neisseria meningitidis, Neisseria gonorrhoeae, Bacteroides spp.

It is resistant to most β-lactamases.

Indications

Severe infectious and inflammatory diseases caused by microorganisms sensitive to cefotaxime, including peritonitis, sepsis, abdominal and pelvic infections, lower respiratory tract infections, urinary tract infections, bone and joint infections, skin and soft tissue infections, infected wounds and burns, gonorrhea, meningitis, Lyme disease.

Prevention of infections after surgery.

Contraindications

Hypersensitivity to cefotaxime and other cephalosporins.

Side effects

From the digestive system:  nausea, vomiting, diarrhea, transient increase in hepatic transaminase activity, cholestatic jaundice, hepatitis, pseudomembranous colitis.

Allergic reactions:  skin rash, pruritus, eosinophilia; rarely-angioedema.

From the hematopoietic system:  with prolonged use in high doses, changes in the picture of peripheral blood (leukopenia, neutropenia, thrombocytopenia, hemolytic anemia) are possible.

From the side of the blood coagulation system:  hypoprothrombinemia.

From the urinary system:  interstitial nephritis.

Effects due to chemotherapeutic action:  candidiasis.

Local reactions:  phlebitis (with intravenous use), soreness at the injection site (with intravenous use).

The interaction

of Cefotaxime, suppressing the intestinal flora, interferes with the synthesis of vitamin K. Therefore, when used simultaneously with drugs that reduce platelet aggregation (NSAIDs, salicylates, sulfinpyrazone), the risk of bleeding increases. For the same reason, when used simultaneously with anticoagulants, there is an increase in the anticoagulant effect.

Concomitant use with aminoglycosides, polymyxin B and loop diuretics increases the risk of kidney damage.

When used concomitantly with drugs that reduce tubular secretion, the concentration of cefotaxime in blood plasma increases.

Probenecid slows down the elimination of cefotaxime by reducing the tubular secretion of the latter.

How to take, course of use and dosage

Adults and children with a body weight of more than 50 kg – 1-2 g every 4-12 hours in / m or iv (jet or drip). Children with a body weight of less than 50 kg – 50-180 mg / kg / day; frequency of use-2-6 times.

Maximum doses:  for adults-12 g / day, for children with a body weight of less than 50 kg – 180 mg/kg/day.

Special instructions

Cefotaxime is used with caution in patients with impaired renal function, indications of colitis in the anamnesis, as well as in newborns.

Patients with hypersensitivity to penicillins may have allergic reactions to cephalosporin antibiotics.

During the treatment period, a positive direct Coombs reaction and a false positive urine glucose reaction are possible.

Caution should be exercised when using concomitant loop diuretics.

Active ingredient

Cefotaxime

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection and infusion